Antagonistic antibodies targeting the inhibitory immune-checkpoint receptor PD-1 or its
ligand PD-L1 are used to treat a wide range of cancer types and can substantially improve …

The cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4)/B7 and programmed death 1
(PD-1)/programmed cell death-ligand 1 (PD-L1) are two most representative immune …

Immunotherapies that target PD-1/PD-L1 axis have shown unprecedented success in a wide
variety of human cancers. PD-1 is one of the key coinhibitory receptors expressed on T cells …

Expression of programmed death-ligand 1 (PD-L1) is frequently observed in human
cancers. Binding of PD-L1 to its receptor PD-1 on activated T cells inhibits anti-tumor …

The engagement of programmed cell death protein 1 (PD-1; encoded by the PDCD1 gene)
receptor expressed on activated T cells and its ligand, programmed death-ligand 1 (PD-L1; …

Tumor suppressor genes cooperate with each other in tumors. Three important tumor
suppressor proteins, retinoblastoma (Rb), p53, phosphatase, and tensin homolog deleted …

With recent approvals for multiple therapeutic antibodies that block cytotoxic T lymphocyte
associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) in melanoma …

Genetic screens in cancer cell lines inform gene function and drug discovery. More
comprehensive screen datasets with multi-omics data are needed to enhance opportunities …

RNA methylation, a prevalent post-transcriptional modification, has garnered considerable
attention in research circles. It exerts regulatory control over diverse biological functions by …

Immune checkpoint molecules, including inhibitory and stimulatory immune checkpoint
molecules, are defined as ligand–receptor pairs that exert inhibitory or stimulatory effects on …